Xing-Jie Liang - Biography#

Professor Xing-Jie Liang received his Ph.D from the National Key Laboratory of Biomacromolecules at the Chinese Academy of Sciences. He completed his postdoc with Dr. Michael M. Gottesman (member of the National Academy of Sciences (NAS, USA) and Deputy Director of National Institute of Health (NIH) at the NCI Laboratory of Cell Biology. Afterwards, he worked as a Research Fellow for glioma treatment at the National Institute of Neurological Diseases and Strokes (NINDS). He also served as Assistant Professor at the Department of Radiology, Howard University School of Medicine.

Currently, Prof. Liang holds key positions in Chinese academia including Deputy Director of Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Principal investigator at the Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China.

Professor Liang is also an elected member of the American Institute for Medical and Biological Engineering (AIMBE), as well as a Faculty Member of F1000 Research. He is also a founding member of International Society of Nanomedicine and current president of the Chinese Association of Nanobiology (CANB). He serves as director and participates as a member for several chemicals and materials-related committees and associations, such as China Society of Biomaterials (CSBM) and Chinese Pharmaceutical Association (CPA).

Prof. Liang published over 320 peer-reviewed papers, including articles in Nature Nanotechnology, PNAS, Advanced Materials, Cancer Research, and Nature Communications. His research interests are focused on compatible biomaterials as nanocarrier synthesized for improving the therapeutic efficiency. One of Prof. Liang’s most recent achievements was the successful development of Nanomicelle Injection with Irinotecan, an IND approved by the Chinese Food and Drug Administration (CFDA) currently underway for clinical trials Phase II.